Johnson & Johnson, Janssen And Changzhou Yabang-QH Pharmachem To Jointly Establish Anti-Worm Drug Base
This article was originally published in PharmAsia News
Johnson & Johnson, Janssen Pharmaceutica NV and Changzhou Yabang-QH Pharmachem recently began construction of their co-designed raw pharmaceutical materials base in Changzhou High-tech District. Of the total investment of about RMB 57 million, the first phase will receive a RMB 35 million capital injection. The facility, which is compliant with European and U.S. GMP, will go into production within this year. At the same time, the center will apply for Europe COS and FDA authentication with Janssen's aid. When completed, the facility will be China's largest anti-worm drug production, research and export base. Most of the expanded products will go to global high-end markets such as the U.S., Europe and Australia. (Click her for more - Chinese Language)
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.